Dispelling the myth: The use of renin-angiotensin blockade in atheromatous renovascular disease

Nephrology Dialysis Transplantation

Volumn 27, Issue 4, 2012, Pages 1403-1409

  Chrysochou, Constantina ^a   Foley, Robert N ^b   Young, James F ^a   Khavandi, Kaivan ^a   Cheung, Ching M ^a   Kalra, Philip A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

angiotensin receptor blockers; angiotensin converting enzyme inhibitors; atheromatous renovascular disease; cardiovascular events; dialysis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE KIDNEY FAILURE; ACUTE RENAL DETERIORATION; ADULT; AGED; ALLERGIC RASH; ANGIONEUROTIC EDEMA; ARTICLE; ATHEROMATOUS RENOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; COUGHING; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERKALEMIA; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY REVASCULARIZATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; RENIN ANGIOTENSIN BLOCKING; RENOVASCULAR DISEASE; REVASCULARIZATION; SIDE EFFECT; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATHEROSCLEROSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL ARTERY OBSTRUCTION; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84859334893     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr496     Document Type: Article

References (46)

1. Kalra PA, Guo H, Gilbertson DT et al. Atherosclerotic renovascular disease in the United States. Kidney Int 2010; 77: 37-43
2. Guo H, Kalra PA, Gilbertson DT et al. Atherosclerotic renovascular disease in older US patients starting dialysis, 1996 to 2001. Circulation 2007; 115: 50-58 (Pubitemid 46058611)
3. Mailloux LU, Napolitano B, Bellucci AG et al. Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: a 20-year clinical experience.AmJKidneyDis 1994; 24: 622-629 (Pubitemid 24318918)
4. Ihle BU, Whitworth JA, Shahinfar S et al. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis 1996; 27: 489-495 (Pubitemid 26106596)
5. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-2033 (Pubitemid 41773378)
6. Taal MW, Thomson C. Renal Association Clinical Practice Guidelines for the Treatment of Patients with Chronic Kidney Disease. London, UK: British Renal Association guidelines, 2007
7. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87 (Pubitemid 32661190)
8. Treatment of Adults and Children with Renal Failure: Standards and Audit Measures. 3rd edn. London, UK: RCP London and the Renal Association, 2002, 2007
9. Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185 (Pubitemid 38425770)
10. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572 (Pubitemid 37430158)
11. Mancia G, De BG, Dominiczak A et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25: 1751-1762 (Pubitemid 47356612)
12. Wright JR, Shurrab AE, Cooper A et al. Left ventricular morphology and function in patients with atherosclerotic renovascular disease. J Am Soc Nephrol 2005; 16: 2746-2453
13. Harding MB, Smith LR, Himmelstein SI et al. Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol 1992; 2: 1608-1616
14. de Silva R, Loh H, Rigby AS et al. Epidemiology, associated factors, and prognostic outcomes of renal artery stenosis in chronic heart failure assessed by magnetic resonance angiography. Am J Cardiol 2007; 100: 273-279 (Pubitemid 47041998)
15. Makanjuola AD, Suresh M, Laboi P et al. Proteinuria in atherosclerotic renovascular disease. Q J Med 1999; 92: 515-518 (Pubitemid 29430049)
16. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin- convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53
17. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788 (Pubitemid 37093919)
18. Solomon SD, Rice MM, Jablonski A et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006; 114: 26-31 (Pubitemid 44305271)
19. Goldsmith DJ, Reidy J, Scoble J. Renal arterial intervention and angiotensin blockade in atherosclerotic nephropathy. Am J Kidney Dis 2000; 36: 837-843
20. Burke TA, Sturkenboom MC, Lu SE et al. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006; 24: 1193-1200 (Pubitemid 43772328)
21. Franklin SS, Smith RD. Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension. Am J Med 1985; 79: 14-23 (Pubitemid 16222547)
22. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636 (Pubitemid 32322240)
23. Mann JF, Gerstein HC, Pogue J et al. Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. Am J Cardiovasc Drugs 2002; 2: 157-162 (Pubitemid 34835649)
24. Brugts JJ, Boersma E, Chonchol M et al. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial. J Am Coll Cardiol 2007; 50: 2148-2155 (Pubitemid 350117347)
25. Bart BA, Gattis WA, Diem SJ et al. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol 1997; 79: 1118-1120 (Pubitemid 27217073)
26. Hillis GS, Trent RJ, Winton P et al. Angiotensin-converting-enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence? Q J Med 1996; 89: 145-150 (Pubitemid 26053128)
27. British National Formulary (ed). Joint Formulary Committee. 59th edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2010. http://bnf.org/bnf/index.htm (18 May 2010, date last accessed)
28. Suresh M, Laboi P, Mamtora H et al. Relationship of renal dysfunction to proximal arterial disease severity in atherosclerotic renovascular disease. Nephrol Dial Transplant 2000; 15: 631-636 (Pubitemid 30242980)
29. Von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 2007; 18: 800-804 (Pubitemid 350295184)
30. Kalra PA, Guo H, Kausz AT et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int 2005; 68: 293-301 (Pubitemid 43181388)
31. MacDowall P, Kalra PA, O'Donoghue DJ et al. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet 1998; 352: 13-16 (Pubitemid 28306559)
32. Missouris CG, Buckenham T, Cappuccio FP et al. Renal artery stenosis: a common and important problem in patients with peripheral vascular disease. Am J Med 1994; 96: 10-14 (Pubitemid 24043646)
33. Kunz R, Friedrich C, Wolbers M et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48 (Pubitemid 351688350)
34. Hricik DE, Browning PJ, Kopelman R et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renalartery stenosis in a solitary kidney. N Engl J Med 1983; 308: 373-376 (Pubitemid 13187219)
35. The Royal College of Physicians/Renal Association Guidelines. 2006; http://www.renal.org/CKDguide/full/CKDprintedfullguide.pdf (2 May 2010, date last accessed) 36.
36. Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? J Am Geriatr Soc 2002; 50: 1297-1300 (Pubitemid 34774558)
37. van de Ven PJ, Beutler JJ, Kaatee R et al. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int 1998; 53: 986-993 (Pubitemid 28155674)
38. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitorassociated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685-693 (Pubitemid 30140419)
39. Shekelle PG, Rich MW, Morton SC et al. Efficacy of angiotensinconverting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41: 1529-1538 (Pubitemid 36543372)
40. Remuzzi G, Ruggenenti P, Perna A et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004; 15: 3117-3125 (Pubitemid 39578844)
41. Tai DJ, Lim TW, James MT et al. Cardiovascular effects of Angiotensin converting enzyme inhibition or Angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol 2010; 5: 623-630
42. Onuigbo MA, Onuigbo NT. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis. Q J Med 2008; 101: 519-527 (Pubitemid 351911994)
43. Losito A, Errico R, Santirosi P et al. Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. Nephrol Dial Transplant 2005; 20: 1604-1609 (Pubitemid 41418583)
44. Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54: 1570-1580 (Pubitemid 28502899)
45. Weinberg AJ, Zappe DH, Ashton M et al. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol 2004; 24: 340-345 (Pubitemid 39070118)
46. Khosla S, Ahmed A, Siddiqui M et al. Safety of angiotensinconverting enzyme inhibitors in patients with bilateral renal artery stenosis following successful renal artery stent revascularization. Am J Ther 2006; 13: 306- (Pubitemid 44492249)